Literature DB >> 12704160

Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.

Thomas R Kozel1, Stuart M Levitz, Françoise Dromer, Marcellene A Gates, Peter Thorkildson, Guilhem Janbon.   

Abstract

Cryptococcus neoformans is surrounded by an antiphagocytic polysaccharide capsule whose primary constituent is glucuronoxylomannan (GXM). Three prominent structural features of GXM are single xylosyl and glucuronosyl side chains and O acetylation of the mannose backbone. Isogenic pairs of O-acetyl-positive and O-acetyl-negative strains (cas1 Delta) as well as xylose-positive and xylose-negative strains (uxs1 Delta) of serotype D have been reported. The cas1 Delta strains were hypervirulent, and the uxs1 Delta strains were avirulent. The goal of this study was to examine the effects of the cas1 Delta and uxs1 Delta mutations on the following: (i) binding of anti-GXM monoclonal antibodies (MAbs) in capsular quellung reactions, (ii) activation of the complement system and binding of C3, (iii) phagocytosis by neutrophils, and (iv) clearance of GXM in vivo. The results showed that loss of O acetylation produced dramatic changes in the reactivities of five of seven anti-GXM MAbs. In contrast, loss of xylosylation produced a substantive alteration in the binding behavior of only one MAb. O-acetyl-negative strains showed no alteration in activation and binding of C3 from normal serum. Xylose-negative strains exhibited accelerated kinetics for C3 deposition. Loss of O acetylation or xylosylation had no effect on phagocytosis of serum-opsonized yeast cells by human neutrophils. Finally, loss of O acetylation or xylosylation altered the kinetics for clearance of GXM from serum and accumulation of GXM in the liver and spleen. These results show that O acetylation and/or xylosylation are important for binding of anti-GXM MAbs, for complement activation, and for tissue accumulation of GXM but do not impact phagocytosis by neutrophils.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704160      PMCID: PMC153297          DOI: 10.1128/IAI.71.5.2868-2875.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.

Authors:  T C MacGill; R S MacGill; A Casadevall; T R Kozel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.

Authors:  G S Pfrommer; S M Dickens; M A Wilson; B J Young; T R Kozel
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

5.  Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.

Authors:  B J Young; T R Kozel
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

6.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

7.  Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans.

Authors:  M Pettoello-Mantovani; A Casadevall; T R Kollmann; A Rubinstein; H Goldstein
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

8.  Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.

Authors:  R Cherniak; L C Morris; B C Anderson; S A Meyer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 9.  Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome.

Authors:  D W Denning; R W Armstrong; B H Lewis; D A Stevens
Journal:  Am J Med       Date:  1991-09       Impact factor: 4.965

10.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  42 in total

1.  Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.

Authors:  Michelle E Maxson; Ekaterina Dadachova; Arturo Casadevall; Oscar Zaragoza
Journal:  Eukaryot Cell       Date:  2006-11-17

2.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans.

Authors:  Neena Jain; Li Li; Ye-Ping Hsueh; Abraham Guerrero; Joseph Heitman; David L Goldman; Bettina C Fries
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

4.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

5.  Reduced phagocytosis and killing of Cryptococcus neoformans biofilm-derived cells by J774.16 macrophages is associated with fungal capsular production and surface modification.

Authors:  Hiu Ham Lee; Jaclyn Del Pozzo; Sergio A Salamanca; Hazael Hernandez; Luis R Martinez
Journal:  Fungal Genet Biol       Date:  2019-07-26       Impact factor: 3.495

6.  Cas3p belongs to a seven-member family of capsule structure designer proteins.

Authors:  Frédérique Moyrand; Yun C Chang; Uwe Himmelreich; Kyung J Kwon-Chung; Guilhem Janbon
Journal:  Eukaryot Cell       Date:  2004-12

7.  A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.

Authors:  Mark Probert; Xin Zhou; Margaret Goodall; Simon A Johnston; Ewa Bielska; Elizabeth R Ballou; Robin C May
Journal:  Infect Immun       Date:  2019-03-25       Impact factor: 3.441

8.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

9.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

10.  A defect in ATP-citrate lyase links acetyl-CoA production, virulence factor elaboration and virulence in Cryptococcus neoformans.

Authors:  Emma J Griffiths; Guanggan Hu; Bettina Fries; Mélissa Caza; Joyce Wang; Joerg Gsponer; Marcellene A Gates-Hollingsworth; Thomas R Kozel; Louis De Repentigny; James W Kronstad
Journal:  Mol Microbiol       Date:  2012-11-01       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.